10% Spectinomycin sulphate+5% Linomycin HCL jekiseni

COMPOSITION

Imwe neimwe ml ine:

Spectinomycin(Sulphate)…100mg

Lincomycin (HCI)…50 mg

FARMACEUTICAL FORM:

Solution Injection

DESCRIPTION

Iko kusanganiswa kwelincomycin uye spectinomycin kunowedzera uye mune dzimwe nguva synergistic.

Spectinomycin inoshanda bacteriostatic kana bactericidal zvichienderana nedoro, kunyanya mabhakitiriya eGram-negative akaita seCampylobacter, E. coli neSalmonella spp.Lincomycin inoshanda bacteriostatic kurwisa kunyanya mabhakitiriya eGram-positive seMycoplasma, Treponema, staphylococcus uye Streptococcus spp.Muchinjikwa-kupokana kwe lincomycin ine macrolides inogona kuitika

ZVIRATIDZO

Zvirwere zvemudumbu uye kufema kunokonzerwa nelincomycin uye spectinomycin inonzwisisika micro-organisms, seCampylobacter, E. coli, Mycoplasma, Salmonella Staphylococcus, Streptococcus uye Treponema spp.mumhuru, mbudzi, makwai, imbwa nekatsi.

NZIRA YEKUTARISA

Nejekiseni re intramuscular

DOSAGE:

Mhuru: 1 ml pa10 kg uremu hwemuviri kwemazuva mana.

Mbudzi nehwai: ml pa10 kg uremu hwemuviri kwemazuva matatu.

Katsi nembwa: 1 ml pa5 kg uremu hwemuviri kwemazuva 3-5, pamwe nepamusoro pemazuva makumi maviri nerimwe.

KUBVA NGUVA

Mhuru, mbudzi nemakwai

Zvenyama: mazuva gumi nemana.

Pamukaka: 3 mazuva.

CONTRAINDICATIONS

Hypersensitivity kune lincomycin uye / kana spectinomycin

Kudzora kumhuka dzine kusagadzikana renal uye/kana hepatic basa

Kushandiswa panguva imwe chete kwepenicillins, cephalosporins, quinolones uye

cyclorine.

SIDE EFFECTS

Hypersensitivity reactions.

Nguva pfupi mushure mejekiseni kurwadziwa kudiki, kuputika kana manyoka zvinogona kuitika

STORAGE:

Dzivirira kubva kuzuva rakananga uye chengetedza pasi pe30 ℃

Hebei Veyong Pharmaceutical Co., Ltd, yakavambwa muna 2002, iri muShijiazhuang City, Hebei Province, China, padyo neguta guru Beijing.Iye ihombe GMP-yakasimbiswa veterinary drug bhizinesi, ine R&D, kugadzira uye kutengesa kweVeterinary APIs, gadziriro, premixed feed uye feed additives.SeProvincial Technical Center, Veyong yakamisa hurongwa hweR&D hwemishonga mitsva yezvipfuyo, uye ndiyo inozivikanwa pasi rose tekinoroji innovation yakavakirwa bhizinesi rezvipfuyo, kune makumi matanhatu neshanu nyanzvi.Veyong ine mabhesi maviri ekugadzira: Shijiazhuang neOrdos, iyo iyo Shijiazhuang base inovhara nzvimbo ye78,706 m2, ine 13 API zvigadzirwa zvinosanganisira Ivermectin, Eprinomectin, Tiamulin Fumarate, Oxytetracycline hydrochloride ects, uye 11, gadziriro yekugadzira oral poda, mitsara yekugadzira oral. , premix, bolus, mishonga yezvipembenene nemishonga inouraya utachiona, ects.Veyong inopa APIs, anopfuura zana ega- label gadziriro, uye OEM & ODM sevhisi.

Veyong inokoshesa zvikuru manejimendi eEHS(Environment, Health & Safety) system, uye yakawana ISO14001 uye OHSAS18001 zvitupa.Veyong yakanyorwa mumabhizinesi ari kusimukira maindasitiri muHebei Province uye inogona kuve nechokwadi chekuenderera mberi kwezvigadzirwa.

Veyong yakamisa hurongwa hwekutonga kwemhando yakakwana, yakawana chitupa cheISO9001, chitupa cheChina GMP, chitupa cheAustralia APVMA GMP, chitupa cheEthiopia GMP, chitupa cheIvermectin CEP, uye yakapasa ongororo yeUS FDA.Veyong ine timu yehunyanzvi yekunyoresa, kutengesa uye tekinoroji sevhisi, kambani yedu yakawana kuvimba nerutsigiro kubva kune akawanda vatengi nemhando yepamusoro yechigadzirwa, yepamusoro-yemhando yepamusoro-yekutanga kutengesa uye mushure mekutengesa sevhisi, yakakomba uye yesainzi manejimendi.Veyong yaita kushandira pamwe kwenguva refu nemabhizinesi mazhinji anozivikanwa pasi rose emishonga yemhuka ane zvigadzirwa zvinotengeswa kuEurope, South America, Middle East, Africa, Asia, etc. kupfuura nyika makumi matanhatu nematunhu.